Drug companies are using intellectual-property laws to price-gouge the public, and even Republicans don’t like it.
Big Pharma
Posted inHealth and Social Policy
Insulin Bill Won’t Help Many Insulin Patients
A proposed cap on co-payments won’t do anything for those without insurance.
Posted inCoronavirus
U.S., EU Back Pharma in Denying Access to Lifesaving COVID Products
A compromise effort to waive intellectual-property rights for vaccines, treatments, and tests will do little to expand supply, experts believe.
Posted inPolitics
To Unify the Country, Biden Must Name Corporate Villains
Stephen Schwarzman is a political villain out of a comic book. Biden should needle him mercilessly.
Posted inHealth and Social Policy
Biden’s Big Chance to Lower Drug Prices
A decision on whether to open a costly cancer drug to generic competition will be made shortly. It doesn’t require congressional approval.
Posted inHealth and Social Policy
Making the Next Coronavirus Vaccine Truly Public
The vaccine developed at the Walter Reed Army Institute should not be privatized for maximum profit.
Posted inMoney, Politics, and Power
Rollups: The Emerging Magic Mushroom Monopoly
Compass Pathways has been aggressively using patent claims to corner the market on psychedelic-assisted treatments.
Posted inHealth and Social Policy
Biden Regulators Take Action on Hidden Pharma Monopolies
A proposed rule would eliminate the ability of pharmacy benefit managers to extract profits after a prescription drug is sold.
Posted inMoney, Politics, and Power
Biden’s Pick for FDA Could Squeak Through With Help From Pharma-Funded Republicans
Four Republicans with extensive ties to the pharmaceutical industry plan to support Robert Califf’s Senate confirmation.
Posted inWorking in America
Pharmacists Stage Walkout in Early Unionization Effort
Thousands of pharmacists are protesting low pay and increased workloads.
